COMPARATIVE EVALUATION OF ANTIVIRAL DRUGS IN PATIENTS WITH CHRONIC VIRAL HEPATITIS

Chronic viral hepatitis, caused primarily by hepatitis B virus (HBV) and hepatitis C virus (HCV), represents a significant global health challenge. The introduction of antiviral drugs has revolutionized treatment strategies, aiming to achieve viral suppression and prevent disease progression. This abstract reviews and compares the effectiveness of current antiviral therapies for HBV and HCV. For HBV, nucleoside/nucleotide analogues (NAs) and interferons are mainstays, with drugs like entecavir and tenofovir disoproxil fumarate (TDF) demonstrating high potency and low resistance rates. In contrast, direct-acting antivirals (DAAs) have transformed HCV treatment, achieving cure rates exceeding 95% with minimal side effects. The comparative evaluation considers factors such as viral suppression, resistance profiles, safety, and treatment adherence. Tailoring therapy to individual patient characteristics remains crucial for optimizing outcomes in chronic viral hepatitis management.